Moderna, Inc. (MRNA)

NASDAQ: MRNA · IEX Real-Time Price · USD
+0.56 (0.43%)
Jun 5, 2023, 12:57 PM EDT - Market open
Market Cap 49.98B
Revenue (ttm) 15.06B
Net Income (ttm) 4.78B
Shares Out 381.21M
EPS (ttm) 11.62
PE Ratio 11.23
Forward PE 32.47
Dividend n/a
Ex-Dividend Date n/a
Volume 1,695,156
Open 131.00
Previous Close 130.51
Day's Range 130.60 - 134.59
52-Week Range 115.03 - 217.25
Beta 1.69
Analysts Buy
Price Target 195.64 (+49.26%)
Earnings Date Aug 2, 2023

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2018
Employees 3,900
Stock Exchange NASDAQ
Ticker Symbol MRNA
Full Company Profile

Financial Performance

In 2022, Moderna's revenue was $19.26 billion, an increase of 4.29% compared to the previous year's $18.47 billion. Earnings were $8.36 billion, a decrease of -31.47%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for MRNA stock is "Buy." The 12-month stock price forecast is $195.64, which is an increase of 49.26% from the latest price.

Price Target
(49.26% upside)
Analyst Consensus: Buy
Stock Forecasts


Moderna and Merck reveal new data on individualized cancer treatment

Moderna MRNA, +1.55% and Merck & Co. MRK, +1.43% on Monday released new results from a trial evaluating Moderna's mRNA-based investigational individualized neoantigen therapy in combination with Merck...

Other symbols: MRK
3 hours ago - Market Watch

Moderna cancer vaccine used with Merck Keytruda reduces risk of deadly skin cancer spreading

Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society.

Other symbols: MRK
3 hours ago - CNBC

Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data

Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage...

Other symbols: MRK
4 hours ago - Reuters

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS res...

Other symbols: MRK
5 hours ago - Accesswire

Moderna to Present at Upcoming Conferences in June 2023

CAMBRIDGE, MA / ACCESSWIRE / June 1, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the fol...

3 days ago - Accesswire

Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting

ASCO presentations on Saturday, June 3 at 4:30pm CDT and Monday, June 5 at 3:00pm CDT Moderna to host investor event via webcast on Monday, June 5 at 6pm CDT CAMBRIDGE, MA / ACCESSWIRE / May 30, 2023 ...

6 days ago - Accesswire

Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines

Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc and Moderna Inc in Delaware federal court, again claiming that the companies' COVID-19 vaccines infringe its...

Other symbols: ALNYPFE
1 week ago - Reuters

Moderna says looking for opportunities in China after registering legal entity

U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy.

1 week ago - Reuters

Moderna shares react to Covid resurgence news in China

Yahoo Finance Live discusses a drop in shares of Moderna after a report of a resurgence of Covid in China.

1 week ago - Yahoo Finance

Report of new COVID wave in China pushes shares of vaccine makers higher

Dr. Kavita Patel, fmr. White House health policy director, joins 'Fast Money' to discuss the latest reports of a possible uptick of COVID cases in China, the immunity situation in the country, and the...

Other symbols: BNTXJNJPFE
1 week ago - CNBC Television

Here's what Pfizer and Moderna say is next for their Covid vaccines

Pfizer and Moderna are ushering in a new era for their Covid shots that aims to simplify what people need to do to coexist with the virus.

Other symbols: PFE
2 weeks ago - CNBC

TipRanks reveals the top 10 health care sector analysts of the past decade

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

2 weeks ago - CNBC

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement To date, mRNA-3927 has been generally well-tolerated at the doses administered, with encouraging ear...

2 weeks ago - Accesswire

Rates Have Risen. Here Are 5 Stocks With Little Debt

Thanks to Jerome Powell and his crew at the Federal Reserve, interest rates are about five percentage points higher than they were a year ago. For stock pickers, that means that debt once again matter...

1 month ago - GuruFocus

Moderna stock closes higher on earnings beat, unexpected profit

Yahoo Finance Live anchors Akiko Fujita and Seana Smith discuss a rise in shares of Moderna as the company's Q1 earnings beat exceeded investor expectations.

1 month ago - Yahoo Finance

COVID-19 ‘is not leaving the planet,' Moderna CEO says

Moderna Therapeutics CEO Stéphane Bancel joins Yahoo Finance Live to discuss first-quarter earnings, COVID-19 vaccine sales, profit growth, and the outlook for the biotechnology company's RSV vaccine.

1 month ago - Yahoo Finance

Moderna stock rises on Q1 earnings, positive vaccine guidance

Yahoo Finance Live's Rachelle Akuffo and Brad Smith discuss the rise in stock for Moderna following first-quarter earnings.

1 month ago - Yahoo Finance

Moderna Stock Pops on Surprise Earnings Beat

An unexpected profit and promising news on a deal with the EU boosted Moderna stock.

1 month ago - Kiplinger

Moderna CEO Stéphane Bancel on surprise Q1 profit, post-Covid future

Moderna CEO Stéphane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, what's next for the biotech company in a post-Covid future, and more.

1 month ago - CNBC Television

Moderna posts surprise quarterly profit despite waning demand for Covid vaccines

Moderna maintained its full-year guidance of around $5 billion in revenue from its Covid vaccine, its only marketable product.

1 month ago - CNBC

Moderna stock up premarket after posting surprise profit and revenue that crushed estimates

Moderna Inc.'s stock MRNA, -0.96% rose 1.8% premarket Thursday, after the biotech blew past estimates for first-quarter earnings, even as profit and revenue fell sharply amid dwindling demand for COVI...

1 month ago - Market Watch

Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates

First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19 Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to...

1 month ago - Accesswire

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting

After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase ...

1 month ago - Accesswire

Moderna Reports Earnings. What Comes After Covid Vaccine Will Be the Focus.

As the biotech reports first-quarter earnings, the focus will be on Moderna's pipeline of future vaccines and cancer treatments and whether they can fill the hole left by dwindling Covid vaccine sales...

1 month ago - Barrons

Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines

The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna's Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta, U.S. The Philippines was select...

1 month ago - Accesswire